

Is control of type I error rate needed in Bayesian clinical trial designs?

Elja Arjas * ¹ and Dario Gasbarra²

¹University of Helsinki, Dept. of Mathematics and Statistics, P.O. Box 68
FI-00014 HELSINGIN YLIOPISTO, Finland

²University of Vaasa, Dept. of Mathematics and Statistics, P.O. Box 700
FI-65101 Vaasa Finland

January 31, 2025

Abstract

Practical employment of Bayesian trial designs is still rare. Even if accepted in principle, the regulators have commonly required that such designs be calibrated according to an upper bound for the frequentist type I error rate. This represents an internally inconsistent hybrid methodology, where important advantages from following the Bayesian principles are lost. In particular, all pre-planned interim looks have an inflating multiplicity effect on type I error rate.

To present an alternative approach, we consider the prototype case of a 2-arm superiority trial with dichotomous outcomes. The design is adaptive, using error control based on sequentially updated posterior probabilities, to conclude efficacy of the experimental treatment or futility of the trial. As gatekeepers for a proposed design, the regulators have the main responsibility in determining the parameters of the control of false positives, whereas the trial sponsors and investigators will have a natural role in specifying the criteria for stopping the trial due to futility. It is suggested that the traditional frequentist operating characteristics in the design, type I and type II error rates, be replaced, respectively, by Bayesian criteria called *False Discovery Probability* (FDP) and *False Futility Probability* (FFP), both terms corresponding directly to their probability interpretations. Importantly, the sequential error control during the data analysis based on posterior probabilities will satisfy these numerical criteria automatically, without need of preliminary computations before the trial is started. The method contains the option of applying a decision rule for terminating the trial early if the predicted costs from continuing would exceed the corresponding gains.

Keywords: superiority trial, sequential design, likelihood principle, interim analyses, false discovery rate, model calibration, early stopping, predictive probability, utility.

*corresponding author, elja.arjas@helsinki.fi

1 Introduction

A key issue in the literature on adaptive trial designs is the choice of the statistical paradigm: frequentist, Bayesian, and sometimes a hybrid of these. This choice is not only of a theoretical character but has important practical consequences as well. In particular, in the frequentist approach all pre-planned interim looks have an inflating multiplicity effect on type I error rate. On the other hand, if this error rate is bounded from above by a selected α -level, such looks lower the power of the tests that are used. In the Bayesian approach, in contrast, these considerations are redundant because of its reliance on the likelihood principle. The design may then allow for even continuously accounting for stopping times relative to the accumulating outcome data, and this has no modifying effect on the statistical inferences that can be drawn. The result is a much greater flexibility and freedom in selecting and applying adaptive decision rules for running the trial.

Another reason, not less important in its support of the Bayesian methodology, is that posterior probabilities based on trial data provide direct answers to the questions that are of interest, together with a quantification of the uncertainties that are then involved. For example, one may be led to a conclusion of the following kind: "Based on expert judgment, empirical findings from comparable earlier trials and from the observed trial data, there is at least ninety percent probability that the tested experimental treatment is more efficacious, by the margin of the pre-specified MID, than the standard treatment that was used as control." This is in contrast to conventional Null Hypothesis Significance Testing (NHST) framework, where a positive result from the trial, such as concluded efficacy of a new drug, is registered indirectly, as rejection of the Null. The considered test statistic has a probability interpretation only when viewed as the quantile of the sampling distribution based on the corresponding fixed parameter value.

A more elaborate approach to modeling based on the same principles allows also utilization of the tools from Bayesian decision theory, in which the concrete consequences of the possible conclusions from the trial are assessed and then expressed in terms of a utility function.

The arguments in support of the Bayesian methodology in the context of clinical trials have been clear for decades, at least since Berry [5] and Spiegelhalter et al. [57]. However, progress in their practical application has been slow; for reasons, see e.g., Chevret [10] and Lee and Chu [34]. Recent accounts of Bayesian methodology in clinical trials can be found in Lin and Lee [37], Giovagnoli [23], Zhou and Ji [70] and Muehleemann et al. [41]. Worth reading is also Ruberg et al. [48], presenting views on the current position of Bayesian methods in drug development. For a systematic study of the area, the monographs Berry et al. [6] and Lesaffre et al. [36] are recommended.

Every clinical trial design involving human subjects, if it is to be implemented in practice, needs to be approved by the regulatory authorities responsible. Even if the statistical analysis of the trial data would be done in accordance with Bayesian principles, the regulators, as exemplified in the FDA guidelines [19] and [20], commonly require that the consequent type I error rate remains below a given significance level. This has led to a large body of literature on how the parameter values of a Bayesian design might be adjusted to satisfy such a requirement. Examples include Freedman et al. [21], Ventz and Trippa [61], Nikolakopoulos [43], Zhu and Yu [71], Ventz et al. [60], Yu [67] and Shi, Yin, et al. [53]. Notwithstanding the high technical level of these contributions, such strict numerical control of type I error rate generally dampens the advantages of Bayesian designs. The result is a conceptual and methodological hybrid, with elements taken from two different, mutually inconsistent statistical paradigms. Due to

our general opposition against such hybrid methodology, we do not review this literature in more detail; however, if desired, Yu [67] is useful reading for such a purpose.

Instead, and following many earlier authors, we propose that the control of false positives be performed by direct bounding, with a selected error tolerance, of the corresponding posterior probabilities during the data analysis. With this, such error control is not affected by multiplicity considerations in sequentially determined interim analyses.

The regulators' approval of the design must obviously be based on information that is made available already before the trial is started. For this purpose, to replace type I error rate as an operating characteristic, we propose an alternative Bayesian criterion called *False Discovery Probability* (FDP). It has the required natural probability interpretation in the context, as the conditional probability, given that a positive conclusion from the trial is established, of that the conclusion is in fact false. The criterion is directly connected, via a conditional expectation, to the corresponding posterior probabilities that will arise when the trial is run.

While the regulators' main interest and responsibility lies naturally in the control of false positives, the sponsors and the investigators may be more concerned with limiting the possibility of false negatives. In traditional designs, this amounts to calculating in advance a sample size large enough to guarantee, at a given significance level and a given effect difference, a high enough power or, equivalently, small type II error rate. In Bayesian trial designs such preliminary sample size calculations, and their Bayesian variants (e.g., Spiegelhalter [55], Lee [35]), become largely redundant, as these designs allow in principle for continued reassessment of the results, without need to thereby adjust the error bounds.

Similarly to the FDP criterion replacing type I error rate, we propose that a criterion called *False Futility Probability* (FFP) would replace type II error rate as an operating characteristic of the design. It, too, arises via a conditional expectation, from the corresponding posterior probabilities, in this case, of that stopping the trial due to futility would be a false conclusion.

These two ways of stopping the trial can be usefully complemented with a third possibility. It may turn out that neither efficacy nor futility has been concluded even after the trial has been run for rather long, and then appear likely, based on an interim analysis of the data, that this situation would continue even if many more patients would be enrolled, with the total costs thereby also accruing. This brings up the question of whether it would make sense to stop the trial even if the result would thereby remain *inconclusive*. If so, what would be the logical point in time to make such a decision?

This question of early stopping of the trial has been studied in a large body of the clinical trials literature, by employing a mix of traditional frequentist, Bayesian, and hybrid concepts, such as conditional power, predictive power and probability of success. Contributions to the area include Herson [28], Spiegelhalter et al. [57], Spiegelhalter et al. [58], Geisser and Johnson [22], Simon [54] and Johns and Andersen [30], with the works Dallow and Fina [12], Yi et al. [66], Wiener et al. [65] and Saville et al. [51] demonstrating a continued current interest in the topic. The advantages of the Bayesian approach to solving this problem have been explored, e.g., in Dmitrienko and Wang [14], Lee and Liu [33], Saville et al. [52] and Zhou et al. [69], and more recently, in Sambucini [50] and Beall et al. [4]. Particularly relevant to us are Cheng and Shen [9], where this question was studied for 2-arm trials from the perspective of Bayesian decision theory, and Bassi et al. [3], where the approach was extended to multi-arm designs.

The structure of the paper is as follows. In Section 2, we present a general sequential rule for

running a trial, and thereby for concluding efficacy of the experimental treatment or futility of the trial. In Section 3, we show how the concerns of the regulators on false positives can be accounted for without using the concept of type I error rate, suggesting that it be replaced by an alternative criterion that respects the likelihood principle. In Section 4 the decision rules of Section 2 are extended to allow the trial to be stopped early, without having reached a definitive result. Section 5 contains some numerical illustrations. The paper, which has an expository character, ends with a discussion in Section 6.

2 Sequential rules for concluding efficacy or futility

In a 2-arm *superiority trial* the usual goal is to find out whether experimental treatment is better than selected control, the latter representing a commonly used standard treatment. Here, for simplicity, incoming patients could be assumed to be assigned to the treatments according to a random block design of size two; the blocks are then independent and the order inside each block has been randomized, with equal probabilities, in advance. Also, more general sequential assignment rules such as response adaptive randomization (RAR), e.g., Robertson et al. [45], can be employed without changing the presentation below as long as such rules only depend on the past assignments and the corresponding outcomes, and not on the parameters of interest.

Considering, throughout, the prototype case of exchangeable dichotomous outcomes, we denote by \mathcal{D}_n the data sequence consisting of treatment assignments and outcomes of the first n patients. Instead of such systematic monitoring of the data after every new outcome, such measurements are usually registered less often, at *interim* times after σ_n patients have been treated, with $n \geq 1$ and $1 \leq \sigma_1 < \dots < \sigma_{n-1} < \sigma_n$. The sequence $\{\sigma_n, n \geq 1\}$ would then be determined according to some fixed or inductive rule such that σ_{n+1} is always determined by the data \mathcal{D}_{σ_n} .

Even radical thinning of the incoming cumulative data is common in practice, with perhaps only one or two interim analyses performed, and can always be motivated by savings in the logistics and computational costs. However, as noted earlier, due to the reliance on the likelihood principle, interim analyses considered here do not as such carry an "inferential cost", as would be the case if the method would be based on bounding the type I error rate. In particular, concepts such as α -spending functions are here irrelevant.

Denote by θ_0 and θ_1 the model parameters, the unknown success rates of the dichotomous outcomes from, respectively, the control and the experimental arms. Given (θ_0, θ_1) , the outcomes from the two arms are assumed to be independent, both i.i.d. given the respective parameter. Boldface notation is here an indication of that, in Bayesian modeling, they are treated as random variables. Let π_e and π_f denote the (joint) prior distributions for (θ_0, θ_1) , approved, respectively, by the regulators and the trial investigators. The subscripts e and f refer, as is explained below, to the primary role of the regulators in establishing *efficacy* of the experimental treatment, and that of the investigators for concluding *futility* of the trial. Accordingly, denote by \mathbb{P}_{π_e} and \mathbb{P}_{π_f} the corresponding joint probabilities on the product space of the parameters (θ_0, θ_1) and of possible data sequences $\{\mathcal{D}_n; 1 \leq n \leq N_{\max}\}$; here N_{\max} is the finite maximal trial size, fixed as part of the design.

Remark. The idea of introducing and utilizing different prior distributions, representing different background information and attitudes of the interested parties, appears to have been first

presented in Kass and Greenhouse [31], see also Spiegelhalter et al. [58] and Spiegelhalter [55]. Some aspects relating to the choice of the priors π_0 and π_1 are presented later in subsection 3.3.

The primary interest of the regulators, that of guarding against false positives, can now be expressed in a straightforward manner, by systematically computing posterior probabilities of the form $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n})$. If such a posterior probability falls below a given threshold value ε_e , say, the trial is stopped and *efficacy* of the experimental treatment in comparison to control is concluded. The threshold ε_e represents then the risk level for false conclusion, which the regulators have deemed acceptable in the context. In here, a positive value of the *minimal important difference* (MID) Δ provides some extra protection to the control arm in such a comparison. If no such extra protection is needed, one can simply choose $\Delta = 0$.

A similar criterion corresponds to the interests of the investigators. If a posterior probability $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\sigma_n})$ turns out to be below a given ε_f , say, the trial is stopped and its *futility* is concluded. The chances of the experimental treatment being better than the control are then deemed by the investigators to be small enough to justify such a conclusion.

A smaller value of ε_e reflects then a more conservative attitude towards concluding efficacy, and a smaller value of ε_f towards ending the trial due to declared futility. Although based on different concepts of probability and, indeed, on different statistical paradigms, $\varepsilon_e > 0$ and $\varepsilon_f > 0$ can be seen as having operationally similar roles as the bounds for the control of type I and type II error rates in frequentist hypothesis testing.

\mathbb{P}_{π_e} specified by the regulators could generally be expected to be more conservative towards concluding efficacy than \mathbb{P}_{π_f} specified by the investigators, so that

$$\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}) \leq \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}). \quad (2.1)$$

A sufficient condition for this is that the distributions of $\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0$ with respect to the priors π_0 and π_1 satisfy the monotone likelihood ratio (MLR) property, e.g., Marshall et al. [38].

We assume that $\varepsilon_e + \varepsilon_f < 1$, which together with (2.1) implies that the defining conditions $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}) < \varepsilon_e$ and $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\sigma_n}) < \varepsilon_f$ cannot be simultaneously satisfied for the same \mathbf{D}_{σ_n} . If either one of them holds for some σ_n , the trial is stopped and the other one will never materialize. In practice, ε_e and ε_f are selected to be small, and then such co-occurrence is ruled out even if the inequality (2.1) may not hold.

To summarize, let

$$\boldsymbol{\tau} = \inf\{1 \leq \sigma_n \leq N_{\max} : \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}) < \varepsilon_e \text{ or } \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\sigma_n}) < \varepsilon_f\} \quad (2.2)$$

be the time at which the trial is stopped for either of these two reasons. We then define the random variables

$$\boldsymbol{\tau}_e = \boldsymbol{\tau} \text{ if } \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\boldsymbol{\tau}}) < \varepsilon_e, \text{ and } \boldsymbol{\tau}_e = \infty \text{ otherwise} \quad (2.3)$$

and

$$\boldsymbol{\tau}_f = \boldsymbol{\tau} \text{ if } \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\boldsymbol{\tau}}) < \varepsilon_f, \text{ and } \boldsymbol{\tau}_f = \infty \text{ otherwise.} \quad (2.4)$$

Thus $\boldsymbol{\tau}$, $\boldsymbol{\tau}_e$ and $\boldsymbol{\tau}_f$ are *stopping times* relative to the observed treatment assignment and outcome histories $\{\mathbf{D}_{\sigma_n}; 1 \leq n \leq N_{\max}\}$. Clearly $\boldsymbol{\tau} = \boldsymbol{\tau}_e \wedge \boldsymbol{\tau}_f$. A finite value of $\boldsymbol{\tau}_e$ signals that

the trial is stopped due to concluded efficacy, and a finite value of τ_f due to concluded futility. These two ways of stopping the trial can, by employing a decision function notation $\delta(\cdot)$, be written as:

(D:i) $\delta(\mathbf{D}_{\sigma_n}) = d_e$: on observing a value $\tau_e = \sigma_n \leq N_{\max}$, the trial is stopped and the experimental treatment is declared to be *effective (superior)* relative to the control, allegedly because it is believed that $\{\theta_1 - \theta_0 > \Delta\}$ holds; then $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 > \Delta | \mathbf{D}_{\tau_e} \cap \{\tau_e < \infty\}) > 1 - \varepsilon_e$.

(D:ii) $\delta(\mathbf{D}_{\sigma_n}) = d_f$: on observing a value $\tau_f = \sigma_n \leq N_{\max}$, the trial is stopped and declared to have ended in *futility*, allegedly because it is believed that $\{\theta_1 - \theta_0 < 0\}$ holds; then $\mathbb{P}_{\pi_f}(\theta_1 - \theta_0 < 0 | \mathbf{D}_{\tau_f} \cap \{\tau_f < \infty\}) > 1 - \varepsilon_f$.

This leads to a simple inductive rule for running the trial: Suppose that, after observing the treatment and outcome data \mathbf{D}_n from the first n patients, neither $\tau_e \leq n$ nor $\tau_f \leq n$ holds. Then one more patient, with index $n + 1$, is assigned to treatment as prescribed by the rule for treatment assignments, such as a previously fixed block randomization, and the outcome is observed. Using a decision function notation, we write this as:

(D:iii) $\delta(\mathbf{D}_{\sigma_n}) = d_c$: for $n < \tau = \tau_e \wedge \tau_f$, d_c signifies the decision to continue the trial after time n by enrolling and treating one more patient.

The stopping rule is then updated by replacing \mathbf{D}_{σ_n} by $\mathbf{D}_{\sigma_{n+1}}$, i.e., by asking, after an additional outcome has been measured, whether either $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \mathbf{D}_{\sigma_{n+1}}) < \varepsilon_e$ or $\mathbb{P}_{\pi_f}(\theta_1 - \theta_0 \geq 0 | \mathbf{D}_{\sigma_{n+1}}) < \varepsilon_f$ would hold. This inductive process can in principle be continued until reaching the maximal trial size $\sigma_n = N_{\max}$. If neither d_e nor d_f is concluded by then, the trial ends with:

(D:iv) $\delta(\mathbf{D}_{N_{\max}}) = d_{\emptyset}$: when neither $\tau_e = \sigma_n$ nor $\tau_f = \sigma_n$ is observed for some $\sigma_n \leq N_{\max}$, the trial ends at $\sigma_n = N_{\max}$ by declaring its result to be *inconclusive*.

Of course, these sequential decision rules can be employed only if the trial is not completely blinded. At the very least, members of the Data Safety and Monitoring Committee (DSMB) need to know, at time σ_n , whether either $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \mathbf{D}_{\sigma_n}) < \varepsilon_e$ or $\mathbb{P}_{\pi_f}(\theta_1 - \theta_0 \geq 0 | \mathbf{D}_{\sigma_n}) < \varepsilon_f$ holds.

On the other hand, once the trial has ended at some $\sigma_n = \tau = \tau_e \wedge \tau_f \leq N_{\max}$, the entire posterior distributions $\mathbb{P}_{\pi_e}((\theta_1, \theta_0) \in | \mathbf{D}_{\tau} \cap \{\tau < \infty\})$ and $\mathbb{P}_{\pi_f}((\theta_1, \theta_0) \in | \mathbf{D}_{\tau} \cap \{\tau < \infty\})$ could in principle be revealed. For example, one can then compute, with respect to these posteriors, expected values of functions of suitably defined utility values, as in equations 4.1 and 4.2 in Section 4.

An extension of **(D:iv)**, providing a utility based decision rule for an early stopping of the trial, is considered later in Section 4.

3 Satisfying the requirements of the regulators

3.1 Background

Practical implementation of trial design always needs to be approved by the responsible regulatory authorities. This creates a potential problem for Bayesian designs, because the standard requirement of the regulators is stated in frequentist terms, as an upper bound for type I error

rate.

For example, Venz and Trippa [61] write as follows: "Concepts, such as the type I error probability, are required to be part of the study design to gain regulatory approval for a treatment", adding later "If necessary, the investigator adjusts tuning parameters to obtain a design that satisfies a pre-specified constraint on the type I error probability." This requirement of adjusting the parameters of a proposed Bayesian design, to be compatible with a given bound for type I error rate, is found also in the FDA guidelines [19] and [20]. Zhou and Ji [70], in their recent review paper on sequential Bayesian trial designs, call this approach *The Frequentist-oriented Perspective*.

There are many examples in the statistical literature on how the settings of a Bayesian design might be adjusted to match the type I error bound, e.g., Freedman et al. [21], Grieve [25], Nikolakopoulos [43], Zhu and Yu [71], Shi, Yin, et al. [53] and Lee [35]. Strict enforcement of a numerical control rule, which has its origin in the frequentist tradition, not only necessitates the introduction of modeling apparatus that would not be necessary from a Bayesian perspective, but makes the Bayesian approach literally subordinate to frequentist control. In particular, even though the decision rule **(D:i)** itself respects the likelihood principle, the multiplicity problem and the consequent inflationary behavior of this criterion are then brought back, now as if through the back door. A more detailed discussion of this is deferred to subsection 3.3.

To qualify as a solution, type I error control would have to be replaced by another criterion that would both (i) not conflict with the foundations of Bayesian statistics, including the likelihood principle, and (ii) be an acceptable tool to the regulators in their endeavor to guard against false positives.

There are two ingredients in the attempts to find a solution to the problem, one technical and the other procedural. The former consists of changing the focus from type I error rate to a different criterion that arises in a natural way from posterior probabilities considered in the context. The latter is concerned with ways to reach an agreement on how the value of the criterion should be specified in practice, despite the possibly differing preferences as to how probability statements are to be interpreted.

3.2 Proposing a criterion for the regulators' error control

From a Bayesian perspective, during the design stage when the investigators and the regulators discuss appropriate ways to perform error control for a future trial and no actual trial data are yet available, it is natural to consider the conditional predictive probability $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty) = \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta, \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty) / \mathbb{P}_{\pi_e}(\boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$. Here the conditioning event $\{\boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty\}$ is that efficacy of the experimental treatment is concluded in the trial, whereas the considered event $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta\}$ of interest means that the success rate of the experimental new treatment would not exceed that of the control by the required MID, and therefore, that such a conclusion is false. We give the following

Definition. We call the conditional probability $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$ *False Discovery Probability*, abbreviating it as *FDP*.

Remarks. (i) FDP is formally the *posterior* probability of $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta\}$, based on \mathbb{P}_{π_e} and upon making the 'discovery' $\{\boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty\}$. Due to its conditional form, it resembles the quantity $1 - \text{PPV}$, where PPV is the familiar characteristic *Positive Predictive Value* in

laboratory testing, roughly defined as "the likelihood that a person who gave a positive test result does have the disease". The numerical value of PPV is determined, by Bayes' rule, from three ingredients: the prevalence of the disease, together with the sensitivity and the specificity of the test method. PPV has also been used as an instrument in more general contexts, as in the discussion of why so many results from empirical research are erroneous (Ioannidis [29]). FDP is similarly related to the criterion called *False Positive Report Probability* (FPRP), introduced in Wacholder et al. [62] in the context of cancer genetics. In FPRP, the conditioning event is a 'positive report'. It means that a 'statistically significant' result has been obtained from a hypothesis test between alternatives H_0 and H_1 , when using a given significance level α and power $1 - \beta$. The numerical value of FPRP is then determined by Bayes' rule, when also accounting for the prior probabilities of H_0 and H_1 .

(ii) The conditional character in the above criteria is important also quantitatively: For example, suppose that one, in a series of trials, uses systematically $\alpha = 0.05$ and $1 - \beta = 0.80$. Suppose further that only 1 in every 5 of investigated treatments is truly effective, corresponding to prevalence 0.2. A simple computation applying Bayes' rule shows then that 20 percent of positive reports will be false, fourfold the selected α -level. If only 1 in every 10 are truly effective, then 36 percent of the positives are false. For example, in drug development such instances may not be very rare, in which case only selecting some small value for α gives a severely biased impression of efficacy.

(iii) The event $\{\tau = \tau_e < \infty\}$ is of course uncertain at the time the trial design is being contemplated, and may not actually happen when the trial is run. But if no 'discovery' is made, then 'false discovery' is not only unlikely but impossible. Note also that according to the observation scheme of the trial, by time τ_e the complete data sequence \mathbf{D}_{τ_e} have been recorded, thereby giving rise to the posterior probability $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \mathbf{D}_{\tau_e} \cap \{\tau = \tau_e < \infty\})$. The FDP $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \tau = \tau_e < \infty)$ is then the expectation, with respect to \mathbb{P}_{π_e} and given $\{\tau = \tau_e < \infty\}$, of such "more refined" posterior probabilities.

(iv) This probability $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \tau = \tau_e < \infty)$ should obviously be small if the design is to be approved by the regulators. However, the same question still remains to answer as before: If such a numerical bound, say $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \tau = \tau_e < \infty) < \varepsilon$ with $\varepsilon > 0$, is imposed by the regulators, how should the operating characteristics ε_e and ε_f for running the trial be selected to satisfy it? But now the answer is very simple indeed: It suffices to choose $\varepsilon_e \leq \varepsilon$ and then proceed into analyzing the trial data according to the rules **(D:i)** - **(D:iv)** in Section 2.

To complete the technical aspect in our proposed solution, we state the following result:

Proposition. *Suppose that the regulators have specified a joint prior $\pi_e(\theta_0, \theta_1)$ for the success rate parameters of the two arms in the trial. If the selected risk tolerance in **(D:i)** is ε_e , then also, FDP satisfies the same criterion $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \tau = \tau_e < \infty) \leq \varepsilon_e$.*

Proof. By direct calculation

$$\begin{aligned} \mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \tau = \tau_e < \infty) &= \mathbb{E}_{\pi_e}(\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \mathbf{D}_{\tau_e} \cap \{\tau = \tau_e < \infty\}) | \tau = \tau_e < \infty) \\ &< \mathbb{E}_{\pi_e}(\varepsilon_e | \tau = \tau_e < \infty) = \varepsilon_e \quad \square \end{aligned}$$

Remarks. (i) The "inner" conditioning in $\mathbb{P}_{\pi_e}(\theta_1 - \theta_0 \leq \Delta | \mathbf{D}_{\tau_e} \cap \{\tau = \tau_e < \infty\})$ corresponds directly to the logic of the decision rule **(D:i)**. There is no need to perform the rather tedious numerical integration with respect to parameter values (θ_0, θ_1) and to data sequences \mathcal{D}_{τ_e} to

determine the value of $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$ and to find whether it would be below a selected bound ε . This will be automatic if $\varepsilon_e \leq \varepsilon$ and decision rule **(D:i)** is applied systematically in the analysis regardless of the particular data sequence $\{\mathcal{D}_{\sigma_n}\}$ that may come up. In principle, once the design parameters $\pi_0, \pi_1, \varepsilon_e, \varepsilon_f$ and Δ have been selected in the desired way, the trial can be started without, as is presently the common practice, experimenting with preliminary simulations to determine an appropriate sample size. After having actually established that the trial has ended at a finite value of $\boldsymbol{\tau}_e$, and having thereby observed the data $\mathbf{D}_{\boldsymbol{\tau}_e}$, the bound $\text{FDP} \leq \varepsilon_e$ for the probability of false discovery, guaranteed by the above Proposition, can be replaced by the realized value of $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\boldsymbol{\tau}_e})$.

(ii) The decisions during the analysis are always based on the current posterior distribution, not directly on the prior. When more data become available, the conclusions become less sensitive to the choice of the prior. The smaller the value of ε_e , the more outcome data are required before the conditioning event $\{\boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty\}$ can be established, if at all, and the weaker is the dependence of $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\boldsymbol{\tau}_e} \cap \{\boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty\})$ on the prior π_e . If the sensitivity aspect is a real concern to either party, the design can include a compulsory burn-in period such that the decision rules **(D:i)** - **(D:iv)** are activated only after the burn-in period has passed. Technically, this means that σ_1 is selected to be sufficiently large. For a more general discussion of the impact of prior selection in Bayesian trial designs see, e.g., Morita et al. [40].

(iii) In the above analysis, a reported conclusion d_e on efficacy has been interpreted as being false if, in fact, $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta\}$ is true, i.e., the experimental new treatment may be better than the control, but not by the required MID margin $\Delta > 0$. Another possibility, quite plausible in practice, would be to instead use the stronger criterion $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq 0\}$ for interpreting a declared efficacy conclusion to be false and then reserve the term FDP for $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq 0 | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$. Since $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq 0 | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty) \leq \mathbb{P}_{\pi_0}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$, the statement of the Proposition remains valid in this case as well. Yet another possibility is to let simply $\Delta = 0$.

(iv) Unsubstantiated conclusions regarding *futility* are likely to be of much less concern to the regulators than false claims of efficacy, but they should be of interest to the investigators of the trial and the sponsors and stakeholders behind the development of the considered experimental treatment. A declared futility result d_f is unsubstantiated if in fact $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0\}$ is true, i.e., the considered new treatment is at least as good as the control. As an alternative, we could even require that the stronger condition $\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq \Delta\}$, involving a MID $\Delta > 0$, be satisfied in order to make such a judgment. Depending on the choice, we can consider conditional probabilities $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \boldsymbol{\tau} = \boldsymbol{\tau}_f < \infty)$ and $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_f < \infty)$, calling the preferred one FFP for *False Futility Probability*. In full analogy with the above Proposition, we then see that if a risk tolerance ε_f is applied in the analysis of the trial data, consistent with rule **(D:ii)**, we have $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq \Delta | \boldsymbol{\tau} = \boldsymbol{\tau}_f < \infty) \leq \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \boldsymbol{\tau} = \boldsymbol{\tau}_f < \infty) \leq \varepsilon_f$. In other words, the FFP value is automatically bounded by the selected ε_f .

3.3 Selection of priors in a trial design: a critical look

In their recent review on Bayesian sequential trial designs, Zhou and Ji [70] divided the approaches in the literature into three classes, calling them *The Subjective Bayesian Perspective*, *The Frequentist-oriented Perspective* and *The Calibrated Bayesian Perspective*. Below, we follow this taxonomy, providing a short description of each, with some comments. However, we drop the attribute *subjective* from the first one. Even if not intended, it is often understood as having a negative connotation, to mean 'not scientific' (cf. O'Hagan [44]) or even arbitrary,

thereby indirectly giving the impression that statistical methods relying on frequentist ideas would be in some sense *objective*, cf. Efron [17]. Another reason is that, to be approved for practical implementation, a trial design, including its prior, always needs to be assessed by several domain experts; it can therefore perhaps be described as *inter-subjective* but is never a single subject's guesstimate. Finally, one could question whether the other two categories should be called Bayesian at all, as they involve elements that are in direct conflict with the foundations of Bayesian statistics.

The Bayesian Perspective. As such, the models in this category represent the current standard in most Bayesian statistical literature, where probability is understood as an epistemic concept without explicit reference to frequency interpretation.

The choice of the prior is often considered to be a controversial issue, as it can be seen either as an advantage, by providing an opportunity to bring existing subject matter knowledge into the inferential problem, or an inherent weakness of the Bayesian approach, since the results of the data analysis will then depend on how the prior is chosen. In consequence of the latter, many alternative approaches have been introduced, to establish 'non-informative', 'weakly informative' or even 'objective' prior distributions.

Literature surveys on the elicitation of prior distributions can be found in Buck and Daneshkhah [7] and Azzolina et al. [2]. The latter identified altogether 460 articles in this area until Nov. 2020, of which 42 were concerned specifically with applications to clinical trials. About 80 percent of them reported on employing parametric techniques for the elicitation. As prior elicitation is not our focus and the literature on the subject is so vast, we give only some directions for further reading. A key contribution, introducing the idea of a "community" of priors, is Spiegelhalter et al. [58], while Neuenschwander et al. [42] present some ideas on employing historical information on controls. Dallow et al. [11] give useful practical advice for the construction of prior distributions, and the recent survey paper by Mikkola et al. [39] puts the task of prior elicitation into a wider perspective.

Our suggestion above has been to employ two distinct prior distributions in the design: π_e to be reviewed and approved by the regulators for the purpose of concluding *efficacy*, and π_f selected by the trial sponsors and investigators for concluding *futility*. Appropriate specification of such priors will naturally depend strongly on the context considered. Following Spiegelhalter [55], also Kass and Greenhouse [31], π_e may perhaps be chosen to be "sceptical" in that it would "express scepticism about large treatment effects ... and [be seen] as a way of controlling early stopping of trials on the basis of fortuitously positive results." The prior π_f could be similarly described as optimistic, or even "enthusiastic", "with a low chance ... that the true treatment benefit is negative." In addition to employing different priors, one may naturally consider varying threshold values ε_e and ε_f , see, e.g., Fayers et al. [18].

Thereby the roles of π_e and π_f are separated clearly from each other. If, however, the different parties involved would have a similar understanding on the likely values of the effect sizes, they could express this in terms of a consensus prior $\pi_e = \pi_f$.

The practical elicitation of appropriate priors is facilitated considerably by postulating that θ_0 and θ_1 are independent. For π_e this means that $\pi_e(\theta_0, \theta_1) = \pi_e^{(0)}(\theta_0)\pi_e^{(1)}(\theta_1)$, where $\pi_e^{(0)}$ is the prior used for the control arm and $\pi_e^{(1)}$ that for the experimental arm. Similarly, postulated independence in π_f can be written as $\pi_f(\theta_0, \theta_1) = \pi_f^{(0)}(\theta_0)\pi_f^{(1)}(\theta_1)$. These assumptions are commonly justified by their convenience; they allow separate elicitation of the arm specific univariate priors and, moreover, the corresponding posteriors can be updated based on

only outcome data from that same arm. Such prior independence simplifies the computations considerably.

In confirmatory comparison of two treatments prior independence can be defended also on the grounds that the outcomes from one arm then do not influence how the performance of the other arm will be assessed. Moreover, the size of confirmatory trials is typically large, and then data likelihood based on a simple parametric model dominates ultimately the influence of the prior. On the other hand, if some treatments are by domain experts judged to be closely similar, and particularly if outcome data are sparse, prior dependence across the arms may be a useful option to consider. Technically, for dichotomous outcomes, such dependence can be formulated by applying odds ratios of log odds (e.g., Kass and Greenhouse [31] and Spiegelhalter et al. [56]). An alternative idea, based on partial exchangeability, is described in Diaconis [13].

By far the most popular prior distribution arising from dichotomous outcomes is $\text{Beta}(\theta; \alpha, \beta)$, where it is conjugate to the binomial likelihood. Moreover, the sum $\alpha + \beta$ is considered as expressing the strength of the prior information, equivalent to $\alpha + \beta$ observed outcomes. Two Beta-priors, say $\text{Beta}(\theta; \alpha, \beta)$ and $\text{Beta}(\theta; \alpha^*, \beta^*)$, are likelihood ratio ordered, in an appropriate direction, if and only if either $\alpha \leq \alpha^*$ and $\beta \geq \beta^*$ or vice versa. Likelihood ratio ordering between priors implies stochastic ordering, and it is inherited from the priors to the posteriors in case these are based on the same data likelihood (Marshall et al. [38]).

The Frequentist-oriented Perspective. Here, as already mentioned in subsection 3.1, the idea is to apply a Bayesian model in parameter estimation but then trust traditional frequentist criteria in error control. To facilitate comparison to the presentation in Zhou and Ji [70], consider the simple situation, where θ_0 is fixed at a given level $\theta_0 = \theta_0$, effectively reducing the 2-arm setting to a single-arm trial. When expressed in the hypothesis testing framework, letting the MID $\Delta = 0$ and dropping the redundant subscript from the parameter θ_1 of the experimental treatment, we are testing $H_0 : \theta \leq \theta_0$ against $H_1 : \theta > \theta_0$. In addition, a value $\theta_a > \theta_0$ is selected to represent the composite alternative hypothesis H_1 .

Suppose now, as we are concerned with sequential Bayesian designs, that the trial is run by following the rules **(D:i)** - **(D:iv)**, with π_e as the prior for θ . For the purposes of error control in a design following the *frequentist-oriented perspective*, potential future trial data are represented, and substituted for, by synthetic data generated from \mathbb{P}_{θ_0} and \mathbb{P}_{θ_a} . We denote the consequent stopping time τ_e by $\tau_e^{\pi_e, \varepsilon_e}$, to make its dependence on π_e and ε_e explicit in situations in which data come from either \mathbb{P}_{θ_0} or \mathbb{P}_{θ_a} .

A 'Bayesian' type I error rate can now be written as the probability $\mathbb{P}_{\theta_0}(\tau_e^{\pi_e, \varepsilon_e} < \infty)$. Thus, according to the *frequentist-oriented perspective* it is required that, for given significance level $\alpha > 0$, $\mathbb{P}_{\theta_0}(\tau_e^{\pi_e, \varepsilon_e} < \infty) \leq \alpha$. This condition is commonly complemented with $\mathbb{P}_{\theta_a}(\tau_e^{\pi_e, \varepsilon_e} < \infty) \geq 1 - \beta$ for power.

With α and β fixed, these inequalities are not necessarily satisfied by the prior π_e and the threshold ε_e that would be selected when following the *Bayesian perspective*. In this case, they are to be adjusted in some way, as demanded by these frequentist criteria. There is an extensive literature, of which some examples were provided earlier in subsection 3.1, on how such adjustments can be achieved technically.

Such forcing calls for comments. From the *Bayesian perspective*, adjustments of the threshold values ε_e would perhaps appear to be more acceptable than those modifying the prior π_e , as the former would not change the probability \mathbb{P}_{π_e} when applying rule **(D:i)**, possibly only

tightening the requirement for concluding efficacy. In contrast, changing the prior, only to satisfy a numerical condition stemming from a different statistical paradigm, would conflict with the core ideas of Bayesian inference and decision theory.

However, requiring that the ε_e -values be adjusted due to bounding type I error rate by a selected $\alpha > 0$ is not as innocent as it might seem: The reason is that, in sequential decision making, the well-known phenomenon of multiplicity sets again in, with the effect of either inflating type I error rate or lowering the power. Thereby one of the key advantages from following the likelihood principle, viz. that the same threshold value can be used in error control regardless of how many interim analyses are made, is lost.

Note that the computation of the numerical values of $\mathbb{P}_{\theta_0}(\boldsymbol{\tau}_e^{\pi_e, \varepsilon_e} < \infty)$ and $\mathbb{P}_{\theta_a}(\boldsymbol{\tau}_e^{\pi_e, \varepsilon_e} < \infty)$, which are needed in setting up a *frequentist-oriented* Bayesian design, to check that the former is below but close to α and the latter at least $1 - \beta$, requires tedious double integrations, inside with respect to parameter values θ in order to evaluate posterior probabilities, and outside with respect to data sequences \mathcal{D}_{σ_n} sampled from \mathbb{P}_{θ_0} and \mathbb{P}_{θ_a} . Only integrations of the former type are needed when following the *Bayesian perspective*, and they are then conditioned on the trial data \mathbf{D}_{σ_n} observed at interim times σ_n when the trial is run.

The key difference between the operating characteristics type I error rate $\mathbb{P}_{\theta_0}(\boldsymbol{\tau}_e^{\pi_e, \varepsilon_e} < \infty)$ in the *frequentist-oriented* and FDP = $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 \leq \theta_0 | \boldsymbol{\tau} = \boldsymbol{\tau}_e < \infty)$ in the *Bayesian perspective* is of course in their direction of conditioning. It explains also why there is multiplicity and inflation phenomenon in the former but not in the latter: In computing type I error rate one needs to integrate (*sum*) across all sequences \mathcal{D}_{τ_e} ending up with τ_e , whereas, for FDP, as shown in the proof of the Proposition in subsection 3.2, only *averaging* of such probabilities is needed.

The Calibrated Bayesian Perspective. In their review paper, Zhou and Ji [70] provided the following justification to this approach: "Although Bayesian probabilities represent degrees of belief in some formal sense, for practitioners and regulatory agencies, it can be pertinent to examine the operating characteristics of Bayesian designs in repeated practices." By operating characteristics, these authors refer to "the long-run average behaviors of a statistical procedure in a series of (possibly different) trials." The crux here is in the words in parentheses, because the usual operating characteristics, type I and type II error rates, are interpreted as arising from an imaginary series of repetitions of the *same* trial, with fully specified fixed parameter values.

According to the *calibrated Bayesian perspective* outlined in [70], each trial proposed to the regulators for approval is viewed as a random draw from a population of comparable trials "in repeated practices" referred to above, with the variation of treatment success parameters $\boldsymbol{\theta}_i$ in consecutive trials then characterized by a population distribution denoted by π_0 . In one way or another, it is thought that π_0 would have an objective existence, and the Bayesian prior π_e used in the analysis of the trial data should then be *calibrated* accordingly.

For this purpose, considering the example of a single-arm trial, Zhou and Ji [70] introduced two operating characteristics, which they called *False Discovery Rate* (FDR) and *False Positive Rate* (FPR). In the words of [70], "The FDR is the relative frequency of false rejections among all trials in which H_0 is rejected, and the FPR is the relative frequency of false rejections among all trials with nonpositive treatment effects θ s."

Extensive simulation experiments were carried out in [70] (in the case of conjugate Normal-Normal models with common mean) by varying both π_0 and π_e . The results, using FDR,

FPR and coverage as performance criteria, were best when $\pi_e = \pi_0$. In this case the selected threshold value corresponding to our ε_e was upheld overall, in agreement with our Proposition of subsection 3.2. The more π_e and π_0 differed from each other, the more the results deteriorated, and more so if the number of interim analyses was increased.

One may well ask, in what sense the population distribution π_0 could be said, excepting simulation experiments, to be 'known' ? If it were, why then not, justified by the idea that success parameter θ_i of a currently considered trial can be thought of as "a random draw from the population distribution π_0 ", make the obvious choice $\pi_e = \pi_0$ for the prior? But if this is done, the consequent mathematics coincides with that of the *Bayesian perspective*. In particular, the above-mentioned operating characteristic FDR coincides mathematically with our FDP, in this case the conditional probability $\mathbb{P}_{\pi_e}(\theta \leq \theta_0 | \tau = \tau_e < \infty)$. Similarly, FPR above can be identified with the *False Positive Probability* (FPP), i.e., the conditional prior predictive probability $\mathbb{P}_{\pi_e}(\tau = \tau_e < \infty | \theta \leq \theta_0)$ of concluding efficacy of the experimental treatment, given that it does in fact not exceed the target θ_0 . The third letters 'R' and 'P' in the acronyms FDR and FPR vs. FDP and FPP, correspond to their respective frequentist and Bayesian interpretations, cf. Storey [59].

The connection between *rates* and (epistemic) *probabilities* works also in the opposite direction, from the latter to the former. Indeed, when starting from a prior π_e and thinking of first drawing, independently, from π_e the parameters θ_i in the different trials, and then, for each trial and conditionally on the respective θ_i , a sequence of independent outcomes, we end up with the usual construction for the canonical probability \mathbb{P}_{π_e} . Recall that the same canonical \mathbb{P}_{π_e} arises also, due to de Finetti's Representation Theorem, from merely postulating infinite exchangeability of the outcomes from the considered trial. In here, the theorem guarantees the existence of a prior π_e , but not its form.

4 A rule for stopping the trial early with an inconclusive result

The sequential scheme presented in Section 2 offers much flexibility in running a clinical trial, and especially compared to traditional designs using a fixed sample size. However, it may well be that neither $\tau_e \leq N_{\max}$ nor $\tau_f \leq N_{\max}$ can be established for even relatively large values of N_{\max} . This is quite likely to be the case if the true success rate of the experimental arm is slightly higher than that of the control, but not by the required MID margin Δ .

This calls for an option, in which there would be a possibility for stopping the trial "early" at times $n < N_{\max}$ when neither d_e nor d_f have so far been concluded and the chances of reaching either one before N_{\max} appear thin. For this, like many other works earlier (e.g., Johns and Andersen [30], Dmitrienko and Wang [14], Lee and Liu [33], Saville et al. [52] and Zhou et al. [69]), we apply ideas from decision theory and predictive inference. Our criterion for early stopping is similar to that employed in Cheng and Shen [9], but differs from it markedly in error control, which in [9] is based on frequentist principles.

The intuition behind such a predictive reasoning is obvious: If, at a considered time σ_n , and if the trial would be continued, the predicted *gains* would exceed the predicted *losses*, then there is a rationale for continuing the trial past σ_n , and otherwise not.

Specification of utility values. Small values of ε_e and ε_f guard against making the conclusions d_e and d_f on false grounds. However, the ultimate purpose of the trial is not to reject but to perform well reasoned selection: conclude d_e when the experimental treatment is truly better than the control, and d_f when it is not better. In consequence, one should consider both the benefits and the costs that will arise from a trial. A good design is one in which the expected benefits are larger than the expected costs. Technically this leads to considering the trial design as a decision problem, with an appropriately defined utility function.

Let G_e be the *gain* from concluding d_e when it is correct, and L_e the *loss* (as an absolute value) when it is false. Similarly, let G_f be the *gain* from concluding d_f when it is correct, and L_f the *loss* (as an absolute value) when it is false. In addition, we introduce a *cost* that incurs from considering (recruiting and treating) each additional patient in the trial.

The choice of appropriate numerical values for G_e , G_f , L_e and L_f will depend on the concrete context considered, and would perhaps most naturally correspond to the financial interests of the stakeholders of the pharmaceutical company which has been responsible for developing the new experimental treatment. Realistically, all these values should be positive, making $-L_e$ and $-L_f$ negative. This holds even for the gain G_f from correctly concluding futility, however disappointing such a conclusion may be from the perspective of the original goals set for the trial. The point is that, if the new treatment does not have the desired target performance, it is better to find this out. Very likely, to justify designing and running a trial at all, G_e should be quite large, and possibly larger than any of these other values. L_f can be quite large as well if the development costs of the new treatment have been high. In confirmatory phase III trials the investments, as well as the expected profits from success, are likely to be much larger than in phase II, and this then reflected in how the utility values are chosen.

Expressing such consequences of the decisions $d \in \{d_e, d_f, d_c, d_\emptyset\}$ in terms of corresponding *utility functions* $U_n(d, (\theta_0, \theta_1))$, $0 \leq n \leq N_{\max}$, then gives, consistent with **D(i) - D(iv)**, the following:

$$\text{(U:i)} \quad U_n(d_e, (\theta_0, \theta_1)) = G_e 1_{\{\theta_1 - \theta_0 > \Delta\}} - L_e 1_{\{\theta_1 - \theta_0 \leq \Delta\}};$$

$$\text{(U:ii)} \quad U_n(d_f, (\theta_0, \theta_1)) = G_f 1_{\{\theta_1 - \theta_0 < 0\}} - L_f 1_{\{\theta_1 - \theta_0 \geq 0\}};$$

$$\text{(U:iii)} \quad U_n(d_c, (\theta_0, \theta_1)) = -1 \text{ for all } (\theta_0, \theta_1);$$

$$\text{(U:iv)} \quad U_n(d_\emptyset, (\theta_0, \theta_1)) = 0 \text{ for all } (\theta_0, \theta_1).$$

In here, -1 is the negative *cost* that incurs from enrolling and treating an additional patient. If the costs of the two treatments considered are markedly different, **(U:iii)** can be modified accordingly. The gains G_e and G_f , and the losses L_e and L_f , are supposed to be measured in the scale of this unit cost.

Another possible refinement concerns **(U:iv)**: the *inconclusive* result d_\emptyset may have considerable practical value that would justify assigning a positive utility value to it. For example, it can be useful, from the perspective of comparable experiments planned in the future, to output summaries from the posterior distribution of (θ_0, θ_1) given the final data. This differs from designs based on standard significance testing. Then, if the trial ends with a non-significant result, the statistical machinery is silent on anything but the fact that the trial was unsuccessful. A p -value larger than the selected α cannot be viewed as providing support to a Null hypothesis.

Since the true parameter values (θ_0, θ_1) are unknown, in a decision problem the corresponding utility function values need to be replaced by their posterior expectations at the considered

time point.

For this, suppose that neither τ_e nor τ_f have been observed by the time data $\mathbf{D}_{\sigma_{n-1}}$ from the σ_{n-1} patients have been registered. In this case, only decisions d_c have been made so far and, according to specifications above, the cumulative utilities have decreased with slope -1 to value $-\sigma_{n-1}$. Consider then the situation at time σ_n after having observed the data \mathbf{D}_{σ_n} . According to the above scheme:

$$\{\tau_e = \sigma_n\} = \{\tau \geq \sigma_n, \delta(\mathbf{D}_{\sigma_n}) = d_e\} = \{\tau \geq \sigma_n, \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}) < \varepsilon_e\}.$$

The posterior expected utility from concluding the experimental treatment to be effective relative to the control, given \mathcal{D}_{τ_e} , is therefore

$$\mathbb{E}_{\pi_f}(U_{\tau_e}(d_e, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_{\tau_e}) = G_e - (L_e + G_e) \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\tau_e}). \quad (4.1)$$

Note that this expectation is taken with respect to \mathbb{P}_{π_f} , since the utilities are meant to correspond to the gains and losses of the stakeholders and investigators, although τ_e appearing in the conditioning on the right is based on considering \mathbb{P}_{π_e} -probabilities. The expectation is positive if, as is natural to assume, $L_e < G_e$ and $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\tau_e})$ is small. The latter follows from the defining condition 2.3 if $\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n}) \leq \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_{\sigma_n})$.

For futility we get

$$\{\tau_f = \sigma_n\} = \{\tau \geq \sigma_n, \delta(\mathbf{D}_{\sigma_n}) = d_f\} = \{\tau \geq \sigma_n, \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\sigma_n}) < \varepsilon_f\}.$$

and

$$\mathbb{E}_{\pi_f}(U_{\tau_f}(d_f, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_{\tau_f}) = G_f - (L_f + G_f) \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_{\tau_f}). \quad (4.2)$$

This expectation is positive if $\varepsilon_f \leq G_f / (L_f + G_f)$. Here, it is likely that the selected loss value L_f would be larger than the corresponding gain G_f .

Note that (4.1) and (4.2) involve convex combinations of the gains and the losses, resulting from the respective decisions d_e and d_f being correct or not correct, both weighted with the corresponding posterior probabilities of the stakeholders and investigators.

The smaller the values of the operating characteristics ε_e and ε_f are, the longer it takes on average until either d_e or d_f can be established based on the accumulated data. This is then reflected in a corresponding increase of the cumulative treatment costs and, when N_{\max} is fixed, in bigger chances of ending the trial with the inconclusive result $\delta(\mathcal{D}_{N_{\max}}) = d_{\emptyset}$.

Let T be the *time horizon* up to which, from the present time σ_n , such predictions are considered, $\sigma_n < T \leq N_{\max}$. A possible choice would be to fix the length of the interval over which the prediction is to be made at some appropriate value, say m , in which case $T = (\sigma_n + m) \wedge N_{\max}$, and another to let that interval extend all the way to $T = N_{\max}$. For any time point t such that $\sigma_n \leq t \leq T$, we obtain the posterior predictive probabilities

$$\mathbb{P}_{\pi_f}(\tau_e = t | \mathcal{D}_{\sigma_n} \cap \{\tau > \sigma_n\}) = \mathbb{P}_{\pi_f}(\tau \geq t, \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_t) < \varepsilon_e | \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\}) \quad (4.3)$$

and

$$\mathbb{P}_{\pi_f}(\tau_f = t | \mathcal{D}_{\sigma_n} \cap \{\tau > \sigma_n\}) = \mathbb{P}_{\pi_f}(\tau \geq t, \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_t) < \varepsilon_f | \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\}). \quad (4.4)$$

Note that \mathbf{D}_t , appearing as a conditioning variable inside the right-hand expressions, is a random variable as it extends into "future" times $t > \sigma_n$ and is only partly determined by the observed data \mathbf{D}_{σ_n} . The corresponding predictive expected cumulative utility, from σ_n onward to T , is then obtained by adding these two expressions for all t , when also accounting for the costs that will arise if neither $\tau_e = t$ nor $\tau_f = t$ is established in \mathbf{D}_t . This gives, with some computation,

$$\begin{aligned}
& \mathbb{E}_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} U_t(\delta(\mathbf{D}_t), (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&= \mathbb{E}_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} 1_{\{\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_t) < \varepsilon_e\}} \mathbb{E}_{\pi_f}(U_t(\delta(\mathbf{D}_t), (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_t) \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&+ \mathbb{E}_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} 1_{\{\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_t) < \varepsilon_f\}} \mathbb{E}_{\pi_f}(U_t(\delta(\mathbf{D}_t), (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_t) \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&+ \mathbb{E}_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} 1_{\{\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_t) \geq \varepsilon_e, \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_t) \geq \varepsilon_f\}} \mathbb{E}_{\pi_f}(U_t(\delta(\mathbf{D}_t), (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_t) \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&= E_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} 1_{\{\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_t) < \varepsilon_e\}} [G_e - (L_e + G_e) \mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \leq \Delta | \mathbf{D}_t)] \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&+ \mathbb{E}_{\pi_f} \left(\sum_{t=\sigma_n}^{\tau \wedge T} 1_{\{\mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_t) < \varepsilon_f\}} [G_f - (L_f + G_f) \mathbb{P}_{\pi_f}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq 0 | \mathbf{D}_t)] \middle| \mathbf{D}_{\sigma_n} \cap \{\tau > \sigma_n\} \right) \\
&- (\mathbb{E}_{\pi_f}(\tau \wedge T) | \mathbf{D}_{\sigma_n}) - \sigma_n.
\end{aligned} \tag{4.5}$$

Numerical values of this predictive expectation can be computed by performing forward simulations from the posterior predictive distribution, given the data \mathbf{D}_{σ_n} , of future trial developments \mathbf{D}_t up to $t = \tau \wedge T$, and finally by applying Monte Carlo averaging to compute the expectation. Due to the double integration, with respect to both the model parameters and the trial developments, these computations are much slower than those needed for computing the posterior probabilities in Section 2. Realistically, such analyses would be made in practice only rarely.

According to the rationale presented above, we now have the following rule for stopping the trial with an inconclusive result:

Rule for inconclusive stopping. *For a selected time horizon T , let*

$$\tau_{\circlearrowleft} = \inf\{0 \leq \sigma_n \leq N_{\max} : \mathbb{E}_{\pi_f}(U_{\tau \wedge T}(\delta(\mathbf{D}_{\tau \wedge T}), (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) | \mathbf{D}_{\sigma_n}) < 0\}. \tag{4.6}$$

If a finite value $\tau_{\circlearrowleft} = \sigma_n \leq N_{\max}$ is observed, the trial is stopped, thereby deciding $\delta(\mathbf{D}_{\sigma_n}) = d_{\circlearrowleft}$.

This rule then extends and replaces the earlier definition (**D:iv**) of d_{\circlearrowleft} .

Remarks. (i) Note that essentially the same procedure, which is used for computing the predictive expectation (4.5), can be applied for computing quantities such as predictive probability of declared efficacy, or of futility, which are considered in a large body of literature, e.g., Dmitrienko and Wang [14], Rufibach et al. [49], Saville et al. [52], and many references therein. For computing the former, it suffices to insert $U_n(d_e, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) = 1_{\{\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq \Delta\}}$ and $U_n(d_f, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) = U_n(d_c, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) = U_n(d_{\circlearrowleft}, (\boldsymbol{\theta}_0, \boldsymbol{\theta}_1)) = 0$ into expression (4.5), and finally ignore its last term, representing the treatment costs.

(ii) With some effort spent on computation, one can explore how different choices of the horizon T would influence the numerical values of the expectation (4.5), and then perhaps choose one that would give it the maximal value. Note also that, in this scheme, no utility value can ever be larger than G_e , the gain from correctly declared efficacy of the new experimental treatment. Since the costs accumulate at the rate of one unit per treated patient, the time horizon after σ_n during which the utility remains positive is bounded by G_e even when no finite N_{\max} has been assumed; for a formal argument, see Theorem 1 in Cheng and Shen [9].

(iii) In the above scheme it is assumed that, in the simulated future trial histories \mathbf{D}_t beyond the present time σ_n , no further comparisons are made between the options d_c and d_o . This simplifies the argument and the consequent numerical computations considerably, as otherwise one would be led to considering a sequence of nested decision problems and thereby to applying recursive backwards induction to evaluate the expression numerically (e.g., Carlin et al. [8], Wathen and Christen [64]). On the other hand, several "present" times σ_n for interim analyses can be fixed in advance, or specified as stopping times, as part of the trial design.

(iv) The above rule for inconclusive stopping is in principle valid also at $n = 0$, when contemplating whether starting a trial for testing a new experimental treatment would be worth the effort and the costs that would thereby incur. At that time no outcome data are yet available from the study itself, and a careful elicitation of the prior is needed to arrive at a meaningful decision concerning such initiation.

5 Numerical illustrations of the characteristic features of the design

In the statistical literature on Bayesian trial designs, the performance of a proposed new method is commonly demonstrated by simulation based numerical results. Of particular interest are then the standard operating characteristics, type I error rate, computed by Monte Carlo simulations where the model parameter values have been selected according to a Null hypothesis of "no difference between the treatments", and power or type II error rate, where one or more selected values for such differences are considered. Extensive illustrations of this kind were considered, for example, in the Supplement of Arjas and Gasbarra [1].

Instead of simulations based on assumed known values of the treatment effect parameters, we consider below the following three more general situations: (a) $\{\theta_1 - \theta_0 > \Delta\}$: new treatment better, by at least the MID Δ , than the control; (b) $\{\theta_1 - \theta_0 < 0\}$: new treatment worse than the control; (c) $\{0 \leq \theta_1 - \theta_0 \leq \Delta\}$: new treatment better than the control, but not by the required MID Δ . In these numerical illustrations we consider the case where π_e and π_f are equal, of the simple form of the product of two Unif(0, 1)-distributions. Denoting the common prior by π , and using the term *sampling prior* introduced in Lee [35], we could say that π , when conditioned on the sets (a), (b) and (c), represent three alternative versions of such sampling priors. The remaining simulation parameters are $\varepsilon_e = \varepsilon_f = 0.05$ and $\Delta = 0.05$, and the utility values $G_e = 2500$, $G_f = 500$, $L_e = L_f = 1000$. The maximal trial size is $N_{\max} = 500$, and time horizon $T = 500$.

Interim analyses are performed after each new observed outcome, i.e., $\sigma_n = n$. Simulations of this type tend to be slow, also as they involve sampling in the entire product space of the parameters (θ_0, θ_1) and of possible data sequences $\{\mathcal{D}_n; 1 \leq n \leq N_{\max}\}$. Variance reduction

and the alternative stochastic filtering approach are discussed in the Appendices.

The results, shown in Figures 1 and 2, are intended as simple qualitative illustrations of the ideas presented earlier, and particularly on how the mutual roles of the three decision alternatives d_e, d_f and d_ϕ change when the *sampling prior* is changed. For example, in the top Figure 1, the blue curve shows the sub-CDF $t \rightarrow \mathbb{P}_\pi(\tau = \tau_e \leq t | \theta_1 - \theta_0 > \Delta)$ for $0 \leq t \leq 500$.

The following crude conclusions can be drawn from Figure 1: in the top figure, with data arising from situation (a), the conditional probabilities for (correctly) concluding d_e by the time the outcomes from t patients have been observed dominate the alternatives d_f and d_ϕ , with the probabilities for d_ϕ remaining small and those for d_f very small; in the middle figure, with data coming from situation (b), the probabilities for (correctly) concluding d_f by time t dominate those for d_e and d_ϕ , with the probabilities for d_ϕ being slightly higher than in (a); in the bottom figure, with data coming from (c), the conditional probabilities for (correctly) concluding d_ϕ by time t dominate the alternatives, with the probabilities for d_e and d_f remaining on relatively low levels.

Figure 2 makes a comparison between a design which includes the possibility of early stopping (left) and one that does not (right), considering jointly the duration τ of the trial and the realized final utility value U_τ at the time it is stopped. The two top figures correspond to the situation where the data are generated according to (a), the middle figures according to (b), and the bottom ones according to (c). In (a) and (b), where the respective correct conclusions are d_e and d_e , non-availability of the early stopping option has the effect that the trial can continue for much longer, in some cases until the maximal trial size N_{max} allowed. However, in both cases, the difference of the conditional expected utilities computed across all trials, between left and right, is small. In (c), the corresponding difference is larger, with the larger value (left) when early stopping is allowed. Here the situation is more subtle, however: recall from **(U:iv)** that $U_n(d_\phi, (\theta_0, \theta_1)) = 0$ for all (θ_0, θ_1) . Therefore, positive final utility values arise only from trials with outcomes d_e or d_f , which are both incorrect in situation (c), and they are more common when early stopping is not allowed (right). The final advantage, in terms of expected utilities, from allowing early stopping is due to that, otherwise, a large proportion of the trials reach the maximal size N_{max} without having concluded either d_e or d_f , but having instead incurred the maximal treatment cost.

6 Discussion

Clinical trials are an instrument for making informed decisions based on experimental data. In phase II trials, the usual goal is to make a comparative evaluation on the efficacy of an experimental treatment to control, and in multi-arm trials, also to each other. More successful treatments among the alternatives considered, if found, can then be selected for a confirmatory analysis in phase III. Essentially the same ideas and methods can be used in both phase II and phase III, and even in a seamless fashion by only making an appropriate adjustment to the threshold values, to correspond to the confirmatory nature of phase III. An additional possibility (cf. Nikolakopoulos [43]) is to use the method of Section 4 as an aid, after having successfully completed phase II, to decide whether it is worthwhile to pursue further into phase III.

Such conclusions should be made using relevant prior information and the data coming from the




Figure 1: Predictive probabilities for different ways of stopping a trial by the time the outcomes from t patients have been observed, subdivided according to the conclusion made (efficacy, futility, or inconclusive). Monte Carlo samples of size 1000 were used in each step for evaluating the considered posterior probabilities and the predictive expected utilities.




Figure 2: An illustration of the effect of including the 'early stopping' -option in the design (for an explanation, see text). Scatter plots and marginal histograms based on simulated samples from the conditional joint distribution of τ and the corresponding conditional expectation of final utility, under \mathbb{P}_π and given the respective efficacy $\{\theta_1 - \theta_0 > \Delta\}$, futility $\{\theta_1 - \theta_0 < 0\}$ and inconclusive $\{0 \leq \theta_1 - \theta_0 \leq \Delta\}$ sampling alternatives. The expectations in each case are computed as sample averages. The simulation parameters are the same as for Figure 1.

trial itself, with the prior being based on trusted expert assessments and, whenever possible, on existing empirical data from comparable treatments. This is precisely what the consequent Bayesian posterior distributions synthesize and express. Compelling arguments justifying their use in the context of clinical trials have been presented in the literature since Berry [5] and Spiegelhalter et al. [58]. For an interesting commentary, see the blog by Harrell [26], which contains also a demonstration of how decisions based on stopping boundaries for Bayesian posteriors are well calibrated.

Of course, such views cannot be enforced on unwilling members of the clinical trials community. An expert in the area, after having read an early version of our text, wrote as follows: "My main concern is that the added value of the suggested approach is no way shown, whereas strong claims are made in favor of Bayesian approaches. To substantiate this, operating characteristics need to be calculated for various true values of the outcome parameters under both treatments, including expected sample size, probability of early stopping for efficacy, probability of early stopping for efficacy, rejection rates (type I error rate or power), false discovery probabilities, true discovery probabilities and probability of a correct decision. These should be compared to frequentist trials (incorporating more traditional interim analyses). This is needed to illustrate whether calculations are feasible, to show how the suggested approach behaves in real-life applications and to show whether control of FDP as proposed results in more efficient trials (as implicitly claimed by the authors) without for instance jeopardizing probability of correct decisions."

According to this expert, a large-scale research program based on both computer simulations and real-life data, should be carried out before presentation of opinions dissenting from the dominant NHST-driven paradigm would be allowed. This is despite that there is increasing concern that the yardstick provided by the NHST paradigm in its commonly practiced form is itself seriously deficient, and that this is an important contributor to the prevailing replication crisis in experimental, including bio-pharmaceutical, research. Worth reading are, for example, the early paper Rozeboom [47], the influential work Ioannidis [29], and Wasserstein and Lazar [63] relating to the ASA *Statement on p-Values and Statistical Significance* (2016).

Second, computer experiments, however extensive, cannot be used for resolving fundamental differences between statistical paradigms. Our proposal for error control, like all Bayesian statistics, rests on assumed validity of the conditionality principle: the results from data analysis are expressed in terms of posterior probabilities, conditioned on the data that were actually observed, and in here probabilities are viewed as expressions of epistemic uncertainty concerning the unknowns, including the values of the model parameters. Frequentist methods for error control, in contrast, take into account outcomes that could have occurred but did not, such as might be observed from hypothetical trials performed under similar conditions in the future, and altogether preclude assigning probabilities to statements concerning parameter values.

Every trial design contains a plan for the procedure according to which patients will be assigned to the treatments, how the outcome data will be analyzed, and on how the conclusions from such analyses are to be drawn. We have considered the latter two aspects. Due to the assumed conditionality principle, the conclusions from the data analysis do not depend on the form of the assignment mechanism if only the consequent likelihood contribution does not depend on the targeted parameters θ_0 and θ_1 . For example, the well-known *response adaptive randomization* (RAR) scheme satisfies this condition if the randomization is performed externally.

The decision rules considered here for superiority trials are easily modified to be appropriate

for *equivalence* and *non-inferiority* trials as well. For example, for the latter, we would be led to considering posterior probabilities of the form $\mathbb{P}_{\pi_e}(\boldsymbol{\theta}_1 - \boldsymbol{\theta}_0 \geq -\Delta | \mathcal{D}_{\sigma_n})$, where Δ is a selected non-inferiority margin. Moreover, the prototype case of dichotomous outcomes measured soon after treatment that was considered here can be modified to other types of outcome data without changing the logical basis of the method, if the relevant posterior probabilities are computable from the accruing data. Normally distributed outcomes, with known variance, are particularly easy to deal with when associated with Normal priors. Extensions into sequential multi-arm designs, and thereby applying adaptive rules for treatment assignment, are also feasible and will be considered in later work.

Proper utilization of Bayesian decision theory for drawing the conclusions would involve, from the very beginning, incorporation of utility functions into a corresponding model (e.g., Rosner [46]). We have made a shortcut in this regard, by first only considering, in Section 2, the threshold values ε_e and ε_f for concluding d_e or d_f , and thereby deferring utility considerations to Section 4, where we considered the option d_\circ of stopping the trial early. Even then, we have not tackled actual optimization issues. With this, we wanted to facilitate the practical implementation of such designs. Specification of appropriate values for ε_e and ε_f should be relatively easy, due to their intuitively straightforward probability interpretation. Elicitation of values for the utilities G_e, G_f, L_e and L_f , although necessary for a fully satisfactory solution of the problem of inconclusive early stopping, requires more careful thought on the part of the domain specialists and the different stakeholders in question.

A central issue in this paper has been our attempt to find a satisfactory answer to the question: If the statistical analysis of trial data is done by applying the tools from Bayesian inference and decision theory, how should one respond to the regulators' guidelines on applying standard frequentist methods for error control?

We have been critical towards the *Frequentist-oriented Perspective*, as described by Zhou and Ji [70], for reasons that are both conceptual and practical. It is a hybrid approach which both relies on the likelihood principle and violates it. For computing the value of type I error rate or of the more general *Family-wise Error Rate* (FWER) one needs to account for the consequent multiplicity problem in testing, and thereby for all possible ways of making errors in concluding efficacy that may turn up when the trial is to be run. We also questioned the practical relevance of the *Calibrated Bayesian Perspective* presented in [70].

Systematic sequential monitoring of the outcomes from the trial, and making corresponding interim checks, may be avoided in practice for valid reasons such as greater complexity in the required logistics, more elaborate computations, or because it is argued that the consequent unblinding could jeopardize the whole study. However, looking from a Bayesian perspective, avoiding interim checks because this would inflate type I error rate, as may be the case when employing the technical machinery of α -spending functions, is an artifact stemming from methods that do not respect the conditionality principle. Additional insightful comments on the implications of applying the likelihood principle in the clinical trials context can be found in Harrell [27].

Our main criticism, more so than against applying frequentist methods in the analysis of trial data in general, is directed against using hybrids of the two statistical paradigms. Merging them in a single trial design only leads to a difficult-to-understand mongrel of a method. Or, to put it differently, one should choose whether to use a belt or suspenders. One is enough, and better than a combination of the two. Calibration, by loosening or tightening one as determined

by the other, only confuses the natural function of the selected means. Thus, our answer to the question in the title of this contribution is a definite 'No'.

Currently the regulators receive rarely requests to handle Bayesian trial designs for possible approval [16], and then, as a rule furnished with a frequentist method for error control. This may, in part, be a consequence of the general perception among the investigators with Bayesian leanings that acceptance without some form of frequentist error control would be difficult or not possible. Methodological conservatism, lacking familiarity with the Bayesian principles, and even prejudices towards such methods based on superficially understood notions of 'subjective' and 'objective' in science (cf. Draper [15]), are not uncommon on either side of the table.

In this situation one would wish that both parties would engage themselves actively in an open discussion, without preconceived fixes of right and wrong. The issues are important and the potential benefits from methodological progress based on conceptually clear and scientifically sound arguments are large. But it takes two to tango...

References

- [1] E. Arjas and D. Gasbarra. "Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective". In: *BMC Med Res Methodol* **22.1** (Feb. 2022).
- [2] D. Azzolina et al. "Prior elicitation for use in clinical trial design and analysis: a literature review". In: *International journal of environmental research and public health* **18.4** (2021), p. 1833.
- [3] A. Bassi et al. "Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials". In: *Stat Methods Med Res* **30.3** (2021), pp. 717–730.
- [4] J. Beall, C. N. Cassarly, and R. L. Martin. "Interpreting a Bayesian phase II futility clinical trial". In: *Trials* **23** (2022).
- [5] D. A. Berry. "Interim analyses in clinical trials: classical vs. Bayesian approaches". In: *Stat Med* **4.4** (1985), pp. 521–526.
- [6] S. M. Berry et al. *Bayesian adaptive methods for clinical trials*. Vol. 38. Chapman & Hall/CRC Biostatistics Series. With a foreword by David J. Spiegelhalter. CRC Press, 2011, pp. xviii+305.
- [7] C. E. Buck and A. Daneshkhah. *Uncertain Judgements: Eliciting Experts' Probabilities. Statistics in Practice*. Wiley, 2006.
- [8] B. P. Carlin, J. B. Kadane, and A. E. Gelfand. "Approaches for optimal sequential decision analysis in clinical trials". In: *Biometrics* (1998), pp. 964–975.
- [9] Y. Cheng and Y. Shen. "Bayesian adaptive designs for clinical trials". In: *Biometrika* **92.3** (2005), pp. 633–646.
- [10] S. Chevret. "Bayesian adaptive clinical trials: a dream for statisticians only?" In: *Stat Med* **31.11-12** (2012), pp. 1002–1013.
- [11] N. Dallow, N. Best, and T. H. Montague. "Better decision making in drug development through adoption of formal prior elicitation". In: *Pharmaceutical Statistics* **17.4** (2018), pp. 301–316.
- [12] N. Dallow and P. Fina. "The perils with the misuse of predictive power". In: *Pharm Stat* **10.4** (2011), pp. 311–317.

- [13] P. Diaconis. “Approximate exchangeability and de Finetti priors in 2022”. In: *Scandinavian Journal of Statistics* **50.1** (2023), pp. 38–53. eprint: <https://onlinelibrary.wiley.com/doi/pdf/10.1111/sjos.12609>.
- [14] A. Dmitrienko and M.-D. Wang. “Bayesian predictive approach to interim monitoring in clinical trials”. In: *Stat Med* **25.13** (2006), pp. 2178–2195.
- [15] D. Draper. “Coherence and calibration: comments on subjectivity and "objectivity" in Bayesian analysis (comment on articles by Berger and by Goldstein)”. In: *Bayesian Anal* **1.3** (2006), pp. 423–428.
- [16] M. O. S. of the Drug Information Association Bayesian Scientific Working Group et al. “Why are not there more Bayesian clinical trials? Perceived barriers and educational preferences among medical researchers involved in drug development”. In: *Therapeutic Innovation & Regulatory Science* (2022), pp. 1–9.
- [17] B. Efron. “Why isn’t everyone a Bayesian?” In: *The American Statistician* **40.1** (1986), pp. 1–5.
- [18] P. M. Fayers, D. Ashby, and M. K. PARMAR. “Tutorial in biostatistics: Bayesian data monitoring in clinical trials”. In: *Statistics in medicine* **16.12** (1997), pp. 1413–1430.
- [19] Food and Drug Administration. *Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials*. 2010.
- [20] Food and Drug Administration. *Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry*. 2019.
- [21] L. S. Freedman, D. J. Spiegelhalter, and M. K. Parmar. “The what, why and how of Bayesian clinical trials monitoring”. In: *Stat Med* **13.13-14** (1994), pp. 1371–1383.
- [22] S. Geisser and W. Johnson. “Interim analysis for normally distributed observables”. In: *Lect Notes Monogr Ser* (1994), pp. 263–279.
- [23] A. Giovagnoli. “The Bayesian Design of Adaptive Clinical Trials”. In: *Int J Environ Res Public Health* **18.2** (2021).
- [24] I. S. Gradshteyn and I. M. Ryzhik. *Table of integrals, series, and products*. Elsevier/Academic Press, 2007, pp. xviii+1171.
- [25] A. P. Grieve. “Idle thoughts of a ‘well-calibrated’ Bayesian in clinical drug development.” In: *Pharmaceutical statistics* **15 2** (2016), pp. 96–108.
- [26] F. Harrell. “Continuous Learning from Data: No Multiplicities from Computing and Using Bayesian Posterior Probabilities as Often as Desired”. In: *Statistical Thinking, Blog* (Oct. 2017).
- [27] F. Harrell. “p-values and Type I Errors are Not the Probabilities We Need”. In: *Statistical Thinking, Blog* (Jan. 2017).
- [28] J. H. Herson. “Predictive probability early termination plans for phase II clinical trials.” In: *Biometrics* **35 4** (1979), pp. 775–83.
- [29] J. P. Ioannidis. “Why most published research findings are false”. In: *PLoS medicine* **2.8** (2005), e124.
- [30] D. Johns and J. S. Andersen. “Use of predictive probabilities in phase II and phase III clinical trials”. In: *J Biopharm Stat* **9.1** (1999), pp. 67–79.
- [31] R. E. Kass and J. B. Greenhouse. “[Investigating Therapies of Potentially Great Benefit: ECMO]: Comment”. In: *Statistical Science* **4.4** (1989), pp. 310–317.

- [32] S. Kulathinal and I. Dewan. “Weighted U-statistics for likelihood-ratio ordering of bivariate data”. English. In: *Statistical Papers* **64.2** (Apr. 2023), pp. 705–735.
- [33] J. J. Lee and D. D. Liu. “A predictive probability design for phase II cancer clinical trials”. In: *Clin Trials* **5.2** (2008), pp. 93–106.
- [34] J. J. Lee and C. T. Chu. “Bayesian clinical trials in action.” In: *Stat Med* **31 25** (2012), pp. 2955–72.
- [35] S. Y. Lee. “Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review”. In: *BMC Medical Research Methodology* **24.1** (2024), p. 110.
- [36] E. Lesaffre, G. Baio, and B. Boulangier. *Bayesian Methods in Pharmaceutical Research*. Ed. by E. Lesaffre, G. Baio, and B. Boulangier. CRC Press, Apr. 2020.
- [37] R. Lin and J. J. Lee. “Novel bayesian adaptive designs and their applications in cancer clinical trials”. In: *Computational and Methodological Statistics and Biostatistics* (2020), pp. 395–426.
- [38] A. W. Marshall, I. Olkin, and B. C. Arnold. *Inequalities: Theory of Majorization and Its Applications*. Springer, 2011.
- [39] P. Mikkola et al. “Prior knowledge elicitation: The past, present, and future”. In: *Bayesian Analysis* **19.4** (2024), pp. 1129–1161.
- [40] S. Morita, P. F. Thall, and P. Müller. “Evaluating the impact of prior assumptions in Bayesian biostatistics”. In: *Statistics in biosciences* **2** (2010), pp. 1–17.
- [41] N. Muehleemann et al. “A Tutorial on Modern Bayesian Methods in Clinical Trials”. In: *Therapeutic Innovation & Regulatory Science* (2023), pp. 1–15.
- [42] B. Neuenschwander et al. “Summarizing historical information on controls in clinical trials”. In: *Clin Trials* **7.1** (2010). PMID: 20156954, pp. 5–18.
- [43] S. Nikolakopoulos. “Hybrid Bayesian-frequentist approaches for randomized trial design in small populations”. PhD thesis. Utrecht University, 2016.
- [44] A. O’Hagan. “Expert Knowledge Elicitation: Subjective but Scientific”. In: *The American Statistician* **73**.sup1 (2019), pp. 69–81. eprint: <https://doi.org/10.1080/00031305.2018.1518265>.
- [45] D. S. Robertson et al. “Response-adaptive randomization in clinical trials: from myths to practical considerations”. In: *Statistical science: a review journal of the Institute of Mathematical Statistics* **38.2** (2023), p. 185.
- [46] G. L. Rosner. “Bayesian methods in regulatory science”. In: *Statistics in biopharmaceutical research* **12.2** (2020), pp. 130–136.
- [47] W. W. Rozeboom. “The fallacy of the null-hypothesis significance test.” In: *Psychological bulletin* **57.5** (1960), p. 416.
- [48] S. J. Ruberg et al. “Application of Bayesian approaches in drug development: starting a virtuous cycle”. In: *Nat Rev Drug Discov* (2023), pp. 1–16.
- [49] K. Rufibach, H. U. Burger, and M. Abt. “Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development”. In: *Pharm Stat* **15.5** (2016), pp. 438–446.
- [50] V. Sambucini. “Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data”. In: *Int J Environ Res Public Health* **18.16** (2021), p. 8816.

- [51] B. R. Saville, M. A. Detry, and K. Viele. “Conditional Power: How Likely Is Trial Success?” In: *JAMA* **329.6** (2023), pp. 508–509.
- [52] B. R. Saville et al. “The utility of Bayesian predictive probabilities for interim monitoring of clinical trials”. In: *Clin Trials* **11.4** (2014), pp. 485–493.
- [53] H. Shi, G. Yin, et al. “Control of type I error rates in Bayesian sequential designs”. In: *Bayesian Anal* **14.2** (2019), pp. 399–425.
- [54] R. Simon. “Some practical aspects of the interim monitoring of clinical trials”. In: *Statistics in medicine* **13.13-14** (1994), pp. 1401–1409.
- [55] D. J. Spiegelhalter. “Incorporating Bayesian Ideas into Health-Care Evaluation”. In: *Statistical Science* **19.1** (2004), pp. 156–174.
- [56] D. J. Spiegelhalter, K. R. Abrams, and J. P. Myles. *Bayesian approaches to clinical trials and health-care evaluation*. Vol. 13. John Wiley & Sons, 2004.
- [57] D. J. Spiegelhalter, L. S. Freedman, and P. R. Blackburn. “Monitoring clinical trials: Conditional or predictive power?” In: *Contr Clin Trials* **7.1** (1986), pp. 8–17.
- [58] D. J. Spiegelhalter, L. S. Freedman, and M. K. B. Parmar. “Bayesian approaches to randomized trials”. In: *J Roy Stat Soc Series A Stat Society* **157.3** (1994), pp. 357–387.
- [59] J. D. Storey. “The positive false discovery rate: a Bayesian interpretation and the q-value”. In: *Ann Stat* **31.6** (2003), pp. 2013–2035.
- [60] S. Ventz, G. Parmigiani, and L. Trippa. “Combining Bayesian experimental designs and frequentist data analyses: motivations and examples”. In: *Applied Stochastic Models in Business and Industry* **33.3** (2017), pp. 302–313.
- [61] S. Ventz and L. Trippa. “Bayesian designs and the control of frequentist characteristics: a practical solution”. In: *Biometrics* **71.1** (2015), pp. 218–226.
- [62] S. Wacholder et al. “Assessing the probability that a positive report is false: an approach for molecular epidemiology studies”. In: *Journal of the National Cancer Institute* **96.6** (2004), pp. 434–442.
- [63] R. L. Wasserstein and N. A. Lazar. “The ASA Statement on p-Values: Context, Process, and Purpose”. In: *The American Statistician* **70.2** (2016), pp. 129–133. eprint: <https://doi.org/10.1080/00031305.2016.1154108>.
- [64] J. K. Wathen and J. A. Christen. “Implementation of backward induction for sequentially adaptive clinical trials”. In: *J Comput Graph Stat* **15.2** (2006), pp. 398–413.
- [65] L. E. Wiener, A. Ivanova, and G. G. Koch. “Methods for clarifying criteria for study continuation at interim analysis”. In: *Pharm Stat* **19.5** (2020), pp. 720–732.
- [66] J. Yi, L. Fang, and Z. Su. “Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: A resampling approach”. In: *Contemp Clin Trials* **33.1** (2012), pp. 138–142.
- [67] Z. Yu. “Unified Approaches for Frequentist and Bayesian Methods in Two-Sample Clinical Trials with Binary Endpoints”. PhD thesis. Medical University of South Carolina, 2019.
- [68] B. G. Zaslavsky. “Bayesian Hypothesis Testing in Two-Arm Trials with Dichotomous Outcomes”. In: *Biometrics* **69.1** (Sept. 2012), pp. 157–163.
- [69] M. Zhou et al. “Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes”. In: *Stat Med* **37.14** (2018), pp. 2187–2207.

- [70] T. Zhou and Y. Ji. “On Bayesian Sequential Clinical Trial Designs”. In: *N Engl J Stat Data Sci* (2023), pp. 1–16.
- [71] H. Zhu and Q. Yu. “A Bayesian sequential design using alpha spending function to control type I error”. In: *Stat Methods Med Res* **26.5** (2017), pp. 2184–2196.

Appendices

A Notes on the analytic and numerical computation of some double Beta integrals

Lemma A.1. 1) A random variable θ is $\text{Beta}(\alpha, \beta)$ -distributed if and only if $(1 - \theta)$ is $\text{Beta}(\beta, \alpha)$ -distributed

2) The incomplete Beta function has representation

$$\begin{aligned} \int_0^x y^{\alpha-1}(1-y)^{\beta-1} dy &= \frac{x^\alpha}{\alpha} {}_2F_1(\alpha, 1-\beta; \alpha+1; x) = \frac{x^\alpha(1-x)^\beta}{\alpha} {}_2F_1(\alpha+\beta, 1; \alpha+1; x) \\ &= \int_{1-x}^1 (1-y)^{\alpha-1} y^{\beta-1} dy = \frac{\Gamma(\alpha)\Gamma(\beta)}{\Gamma(\alpha+\beta)} - \frac{(1-x)^\beta}{\beta} {}_2F_1(\beta, 1-\alpha, \beta+1, 1-x) \end{aligned}$$

where ${}_2F_1(a, b; c; x)$ is the Gauss hypergeometric function.

3) Gauss generalized hypergeometric function satisfies

$$\begin{aligned} \frac{\Gamma(\alpha+\beta)}{\Gamma(\alpha)\Gamma(\beta)} \int_0^1 x^{\alpha-1}(1-x)^{\beta-1} {}_pF_q(a_1, \dots, a_p; b_1, \dots, b_q; xy) dx \\ = {}_{p+1}F_{q+1}(a_1, \dots, a_p, \alpha; b_1, \dots, b_q, \alpha+\beta; y) \end{aligned}$$

4)

$$\begin{aligned} \int_0^1 x^{\gamma-1}(1-x)^{\rho-1}(1-zx)^{-\sigma} {}_2F_1(\alpha, \beta; \gamma; x) dx \\ = (1-z)^\sigma \frac{\Gamma(\gamma)\Gamma(\rho)\Gamma(\gamma+\rho-\alpha-\beta)}{\Gamma(\gamma+\rho-\alpha)\Gamma(\gamma+\rho-\beta)} {}_3F_2(\rho, \sigma, \gamma+\rho-\alpha-\beta; \gamma+\rho-\alpha, \gamma+\rho-\beta; \frac{z}{z-1}) \end{aligned}$$

for $\Re(\gamma), \Re(\rho), \Re(\gamma+\rho-\alpha-\beta) > 0, |\arg(1-x)| < \pi$ (7.512.9 in Gradshteyn and Ryzhik [24]).

5)

$$(1-x)^\alpha = {}_1F_0(\alpha; x) = {}_2F_1(\alpha, \beta; \beta; x)$$

Lemma A.2. 1)

$$\begin{aligned} \mathbb{P}(\theta_1 < \theta_0) &= \frac{\Gamma(\alpha_0+\beta_0)\Gamma(\alpha_1+\beta_1)}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)} \int_0^1 \int_0^x y^{\alpha_1-1}(1-y)^{\beta_1-1} dy x^{\alpha_0-1}(1-x)^{\beta_0-1} dx = \\ &= \frac{\Gamma(\alpha_0+\alpha_1)\Gamma(\beta_0+\beta_1)\Gamma(\alpha_0+\beta_0)\Gamma(\alpha_1+\beta_1)}{\Gamma(\alpha_0+\alpha_1+\beta_0+\beta_1)\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1+1)\Gamma(\beta_1)} \times \\ &= {}_3F_2(\alpha_1+\beta_1, 1, \alpha_0+\alpha_1; \alpha_1+1, \alpha_0+\alpha_1+\beta_0+\beta_1; 1) \end{aligned}$$

where the hypergeometric function ${}_3F_2(a_1, a_2, a_3; b_1, b_2; z)$ is convergent for $|z| < 1$, and also when $|z| = 1$ and $\Re\left(\sum_{k=1}^2 b_k - \sum_{j=1}^3 a_j\right) > 0$.

2) We have also

$$\begin{aligned}\mathbb{P}(\boldsymbol{\theta}_1 < c\boldsymbol{\theta}_0) &= \frac{\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)} \int_0^1 \int_0^{x/c} y^{\alpha_1-1}(1-y)^{\beta_1-1} dy x^{\alpha_0-1}(1-x)^{\beta_0-1} dx = \\ &= \frac{\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)c^{\alpha_0}}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)} \int_0^1 \int_0^u y^{\alpha_1-1}(1-y)^{\beta_1-1} dy u^{\alpha_0-1}(1-cu)^{\beta_0-1} du = \\ &= \frac{\Gamma(\alpha_0 + \beta_0 - 1)\Gamma(\alpha_0 + \alpha_1)\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)c^{\alpha_0}(1-c)^{1-\beta_0}}{\Gamma(\alpha_0 + \alpha_1 + \beta_0 - 1)\Gamma(\alpha_0)^2\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)} \times \\ &= {}_3F_2\left(0, 1 - \beta_0, \alpha_0 + \beta_1 - 1; \alpha_0 + \alpha_1 + \beta_1 - 1; \frac{c}{c-1}\right)\end{aligned}$$

3)

$$\begin{aligned}\mathbb{P}(\boldsymbol{\theta}_1 < \boldsymbol{\theta}_0 + \Delta) &= \\ &= \frac{\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)} \int_0^1 \int_0^{1 \wedge (x+\Delta)} y^{\alpha_1-1}(1-y)^{\beta_1-1} dy x^{\alpha_0-1}(1-x)^{\beta_0-1} dx\end{aligned}$$

For $\Delta > 0$

$$\begin{aligned}&= \frac{\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)\Delta^{\alpha_1}}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)\alpha_1} \int_0^{1-\Delta} \left(1 + \frac{x}{\Delta}\right)^{\alpha_1} {}_2F_1(\alpha_1, 1 - \beta_1; \alpha_1 + 1; x + \Delta) x^{\alpha_0-1}(1-x)^{\beta_0-1} dx \\ &+ \frac{\Gamma(\alpha_0 + \beta_0)}{\Gamma(\alpha_0)\Gamma(\beta_0)} \int_{1-\Delta}^1 x^{\alpha_0-1}(1-x)^{\beta_0-1} dx = \\ &= \frac{\Gamma(\alpha_0 + \beta_0)\Gamma(\alpha_1 + \beta_1)\Delta^{\alpha_1}}{\Gamma(\alpha_0)\Gamma(\beta_0)\Gamma(\alpha_1)\Gamma(\beta_1)\alpha_1} \int_0^{1-\Delta} {}_1F_0(\alpha_1; -\frac{x}{\Delta}) {}_2F_1(\alpha_1, 1 - \beta_1; \alpha_1 + 1; x + \Delta) x^{\alpha_0-1}(1-x)^{\beta_0-1} dx \\ &+ \frac{\Gamma(\alpha_0 + \beta_0)}{\Gamma(\alpha_0)\Gamma(\beta_0)} \frac{\Delta^{\beta_0}}{\beta_0} {}_2F_1(\beta_0, 1 - \alpha_0; \beta_0 + 1; \Delta)\end{aligned}$$

B Innovation Gain formulae updating the posterior in Bayesian Filtering

For $\boldsymbol{\theta} \sim \text{Beta}(\alpha, \beta)$, by using integration by parts we obtain the following Stein equation for the Beta distribution

$$\begin{aligned}\frac{\alpha\beta}{(\alpha + \beta)(\alpha + \beta + 1)} \mathbb{E}_{\alpha+1, \beta+1}[\partial f(\boldsymbol{\theta})] &= \mathbb{E}_{\alpha, \beta}[\boldsymbol{\theta}(1 - \boldsymbol{\theta})\partial f(\boldsymbol{\theta})] = \\ \mathbb{E}_{\alpha, \beta}[(\beta + \alpha)\boldsymbol{\theta} - \alpha] f(\boldsymbol{\theta}) &= \alpha\{\mathbb{E}_{\alpha+1, \beta}[f(\boldsymbol{\theta})] - \mathbb{E}_{\alpha, \beta}[f(\boldsymbol{\theta})]\}\end{aligned}$$

For $f(\boldsymbol{\theta}) = \mathbf{1}(\boldsymbol{\theta} > t)$, $\partial f(\boldsymbol{\theta}) = \Delta_t(\boldsymbol{\theta})$, the Dirac delta function, which gives

$$\begin{aligned}\mathbb{P}_{\alpha+1, \beta}(\boldsymbol{\theta} > t) &= \mathbb{P}_{\alpha, \beta}(\boldsymbol{\theta} > t) + \frac{\Gamma(\alpha + \beta)}{\Gamma(\alpha + 1)\Gamma(\beta)} t^\alpha (1-t)^\beta \\ &= \mathbb{P}_{\alpha, \beta}(\boldsymbol{\theta} > t) + \alpha^{-1} \text{Beta}(\alpha, \beta)^{-1} t^\alpha (1-t)^\beta\end{aligned}$$

which can be used to update the posterior recursively. We have also

$$\mathbb{P}_{\alpha+1,\beta}(\boldsymbol{\theta} \leq t) - \mathbb{P}_{\alpha,\beta}(\boldsymbol{\theta} \leq t) = -\alpha^{-1} \text{Beta}(\alpha, \beta)^{-1} t^\alpha (1-t)^\beta$$

and

$$\begin{aligned} \mathbb{P}_{\alpha,\beta+1}(\boldsymbol{\theta} \leq t) &= \mathbb{P}_{\alpha,\beta+1}(1 - \boldsymbol{\theta} \geq 1 - t) = \mathbb{P}_{\beta+1,\alpha}(\boldsymbol{\theta} \geq 1 - t) = \\ &\mathbb{P}_{\alpha,\beta}(\boldsymbol{\theta} \leq t) + \beta^{-1} \text{Beta}(\alpha, \beta)^{-1} t^\alpha (1-t)^\beta \end{aligned}$$

By integrating we obtain for $\boldsymbol{\theta}_0, \boldsymbol{\theta}_1$ with independent $\text{Beta}(\alpha_i, \beta_i)$ priors

$$\begin{aligned} &(\mathbb{P}_{\alpha_0+1,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1) = \\ &\frac{\Gamma(\alpha_0 + \beta_0) \Gamma(\alpha_1 + \beta_1) \Gamma(\alpha_0 + \alpha_1) \Gamma(\beta_0 + \beta_1)}{\Gamma(\alpha_0 + 1) \Gamma(\beta_0) \Gamma(\alpha_1) \Gamma(\beta_1) \Gamma(\alpha_0 + \alpha_1 + \beta_0 + \beta_1)} \\ &= \frac{\text{Beta}(\alpha_0 + \alpha_1, \beta_0 + \beta_1)}{\alpha_0 \text{Beta}(\alpha_0, \beta_0) \text{Beta}(\alpha_1, \beta_1)} \end{aligned}$$

and

$$\begin{aligned} &(\mathbb{P}_{\alpha_0,\beta_0+1} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 \leq \boldsymbol{\theta}_1) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 \leq \boldsymbol{\theta}_1) \\ &= \frac{\text{Beta}(\beta_0 + \beta_1, \alpha_0 + \alpha_1)}{\beta_0 \text{Beta}(\beta_0, \alpha_0) \text{Beta}(\beta_1, \alpha_1)} \end{aligned}$$

see Zaslavsky [68]. We derive also expressions for the innovation gain in the Bayes filtering formula sequentially updating the posterior distribution

$$\begin{aligned} &(\mathbb{P}_{\alpha_0+1,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1 + \Delta) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1 + \Delta) = \\ &\alpha_0^{-1} \text{Beta}(\alpha_0, \beta_0)^{-1} \text{Beta}(\alpha_1, \beta_1)^{-1} \int_{\Delta^-}^{1-\Delta^+} t^{\alpha_0-1} (1-t)^{\beta_0-1} (t+\Delta)^{\alpha_0} (1-\Delta-t)^{\beta_0} dt \\ &= \alpha_0^{-1} \text{Beta}(\alpha_0, \beta_0)^{-1} \mathbb{E}_{\alpha_1,\beta_1} \left(\{(\boldsymbol{\theta}_1 + \Delta)^+\}^{\alpha_0} \{(1 - \boldsymbol{\theta}_1 - \Delta)^+\}^{\beta_0} \right) = \\ &\frac{\beta_0}{(\alpha_0 + \beta_0)(\alpha_0 + \beta_0 + 1) \text{Beta}(\alpha_1, \beta_1)} \mathbb{E}_{\alpha_0+1,\beta_0+1} \left(\{(\boldsymbol{\theta}_0 - \Delta)^+\}^{\alpha_0-1} \{(1 + \Delta - \boldsymbol{\theta}_0)^+\}^{\beta_0-1} \right) = \\ &\alpha_0^{-1} \text{Beta}(\alpha_0, \beta_0)^{-1} \text{Beta}(\alpha_1, \beta_1)^{-1} \times \\ &\sum_{k=0}^{\infty} \sum_{\ell=0}^k \Delta^k (-1)^\ell \frac{(\beta_0)_\ell (\alpha_0)_{k-\ell}}{\ell! (k-\ell)!} \int_{\Delta^-}^{1-\Delta^+} (1-t)^{\beta_0+\beta_1-\ell-1} t^{\alpha_0+\alpha_1+\ell-k-1} dt \\ &= \alpha_0^{-1} \text{Beta}(\alpha_0, \beta_0)^{-1} \text{Beta}(\alpha_1, \beta_1)^{-1} \times \\ &\sum_{k=0}^{\infty} \sum_{\ell=0}^k \Delta^k (-1)^\ell \frac{(\beta_0)_\ell (\alpha_0)_{k-\ell}}{\ell! (k-\ell)! (\alpha_0 + \alpha_1 + \ell - k)} \times \\ &\left\{ (1 - \Delta^+)^{\alpha_0+\alpha_1+\ell-k} {}_2F_1(\alpha_0 + \alpha_1 + \ell - k, 1 + \ell - \beta_0 - \beta_1; 1 + \alpha_0 + \alpha_1 + \ell - k; 1 - \Delta^+) \right. \\ &\left. - (\Delta^-)^{\alpha_0+\alpha_1+\ell-k} {}_2F_1(\alpha_0 + \alpha_1 + \ell - k, 1 + \ell - \beta_0 - \beta_1; 1 + \alpha_0 + \alpha_1 + \ell - k; \Delta^-) \right\} \end{aligned}$$

with $\Delta^+ = \max\{\Delta, 0\}$ $\Delta^- = \max\{-\Delta, 0\}$, and we have used the generalized Newton binomial formula where $(\alpha)_k = \alpha(\alpha-1)\dots(\alpha-k+1)$ is the Pochhammer symbol. We have also the

updates

$$\begin{aligned}
& (\mathbb{P}_{\alpha_0+1,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 + \Delta < \boldsymbol{\theta}_1) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 + \Delta < \boldsymbol{\theta}_1) = \\
& = -\alpha_0^{-1} \text{Beta}(\alpha_0, \beta_0)^{-1} \mathbb{E}_{\alpha_1,\beta_1} \left(\left\{ (\boldsymbol{\theta}_1 - \Delta)^+ \right\}^{\alpha_0} \left\{ (1 - \boldsymbol{\theta}_1 + \Delta)^+ \right\}^{\beta_0} \right) \\
& (\mathbb{P}_{\alpha_0,\beta_0+1} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1 + \Delta) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1 + \Delta) = \\
& (\mathbb{P}_{\beta_0+1,\alpha_0} \otimes \mathbb{P}_{\beta_1,\alpha_1})(\boldsymbol{\theta}_1 > \boldsymbol{\theta}_0 + \Delta) - (\mathbb{P}_{\beta_0,\alpha_0} \otimes \mathbb{P}_{\beta_1,\alpha_1})(\boldsymbol{\theta}_1 > \boldsymbol{\theta}_0 + \Delta) = \\
& - \beta_0^{-1} \text{Beta}(\beta_0, \alpha_0)^{-1} \mathbb{E}_{\beta_1,\alpha_1} \left(\left\{ (\boldsymbol{\theta}_1 - \Delta)^+ \right\}^{\beta_0} \left\{ (1 - \boldsymbol{\theta}_1 + \Delta)^+ \right\}^{\alpha_0} \right) \\
& (\mathbb{P}_{\alpha_0,\beta_0+1} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 + \Delta < \boldsymbol{\theta}_1) - (\mathbb{P}_{\alpha_0,\beta_0} \otimes \mathbb{P}_{\alpha_1,\beta_1})(\boldsymbol{\theta}_0 + \Delta < \boldsymbol{\theta}_1) \\
& = \beta_0^{-1} \text{Beta}(\beta_0, \alpha_0)^{-1} \mathbb{E}_{\beta_1,\alpha_1} \left(\left\{ (\boldsymbol{\theta}_1 + \Delta)^+ \right\}^{\beta_0} \left\{ (1 - \boldsymbol{\theta}_1 - \Delta)^+ \right\}^{\alpha_0} \right)
\end{aligned}$$

When $\alpha_j, \beta_j \in \mathbb{N}, \forall j = 0, 1, \dots, K$, the innovation gain in the filtering formula for $\mathbb{P}(\boldsymbol{\theta}_0 + \Delta < \boldsymbol{\theta}_1 | \mathcal{D}_t)$ has analytic expression.

C Efficient Monte Carlo approximation

The computation of Beta functions and hypergeometric functions appearing in the innovation formulae for large values of the beta distributions parameters is prone to severe numerical instability. A simple and robust numerical alternative to evaluate the posterior probabilities $\mathbb{P}(\boldsymbol{\theta}_0 > \boldsymbol{\theta}_1 | \mathcal{D}_t)$ and $\mathbb{P}(\boldsymbol{\theta}_1 > \boldsymbol{\theta}_0 + \Delta | \mathcal{D}_t)$ is by using plain Monte Carlo in the most efficient way. Let X, Y be independent random variables with respective cumulative distribution functions F, G . An estimator of

$$\mathbb{P}(X > Y) = \int_{\mathbb{R}} \int_{\mathbb{R}} \mathbf{1}(x > y) F(dx) G(dy),$$

based on independent realizations $(X_k, Y_k : k = 1, \dots, n)$, is given by

$$\widehat{\mathbb{P}}_n(X > Y) = \int_{\mathbb{R}} \int_{\mathbb{R}} \mathbf{1}(x > y) F_n(dx) G_n(dy) = \frac{1}{n^2} \sum_{j=1}^n \sum_{k=1}^n \mathbf{1}(X_j > Y_k),$$

where F_n, G_n are the respective empirical processes. Asymptotically $\sqrt{n}(F_n(x) - F(x)) \rightarrow B(x)$ and $\sqrt{n}(G_n(y) - G(y)) \rightarrow Z(y)$, which are zero mean Brownian bridge processes $B(x), Z(y)$ with respective covariances $\mathbb{E}(B(x)B(x')) = F(x \wedge x') - F(x)F(x')$ and $\mathbb{E}(Z(y)Z(y')) = G(y \wedge y') - G(y)G(y')$. The estimator $\widehat{\mathbb{P}}_n(X > Y)$ is unbiased and, by the functional delta method,

$$\sqrt{n}(\widehat{\mathbb{P}}_n(X > Y) - \mathbb{P}(X > Y))$$

is asymptotically zero mean Gaussian with variance

$$\begin{aligned}
\sigma^2 &= \int_{\mathbb{R}} (1 - F(y))^2 G(dy) - \left(\int_{\mathbb{R}} (1 - F(y)) G(dy) \right)^2 + \int_{\mathbb{R}} G(x)^2 F(dx) - \left(\int_{\mathbb{R}} G(x) F(dx) \right)^2 \\
&= \text{Var}_G(F(Y)) + \text{Var}_F(G(X)).
\end{aligned}$$

Computing \widehat{P}_n requires n independent samples from both distributions F, G , sorting the combined samples and doing on average $2n \log(2n)$ comparisons, achieving asymptotic standard deviation $\sigma n^{-1/2}$. The naive estimator based on the same samples

$$\check{\mathbb{P}}_n(X > Y) = \frac{1}{n} \sum_{k=1}^n \mathbf{1}(X_k > Y_k),$$

requiring n comparisons, is also unbiased and

$$\sqrt{n}(\check{\mathbb{P}}_n(X > Y) - \mathbb{P}(X > Y))$$

is asymptotically Gaussian with zero mean and variance

$$\eta^2 = \mathbb{P}(X > Y) - \mathbb{P}(X > Y)^2 = \mathbb{E}_F(G(X)) - \mathbb{E}_F(G(X))^2 = \mathbb{E}_G(1 - F(Y)) - \mathbb{E}_G(1 - F(Y))^2.$$

For X, X', Y, Y' independent random variables with $X, X' \sim F$ and $Y, Y' \sim G$,

$$\eta^2 - \sigma^2 = \frac{1}{4} \mathbb{E} \left[\left(\mathbf{1}(X > Y) - \mathbf{1}(X > Y') + \mathbf{1}(X' > Y') - \mathbf{1}(X' > Y) \right)^2 \right] \geq 0.$$

In practice the computational cost of comparing variables is much smaller than the cost of sampling random variables, and it is computationally more efficient to make $2n \log(2n) > n$ comparisons in order to achieve the smaller constant $\sigma^2 \leq \eta^2$ in the asymptotic error variance (see also Kulathinal and Dewan [32]).